Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association of the blood eosinophil count with end-organ symptoms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical, Physiologic, and Behavioral Evaluation of Permanently Catheterized NMRI Mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The role of excess reactive oxygen species (ROS) with consequent DNA/RNA damage is now recognized as a hallmark of cancer. In JAK2V617F mutated myeloproliferative neoplasms, ROS have been suggested to be important factors in disease initiation and progression. Ruxolitinib is the most widely used drug for myelofibrosis, because it improves symptom-score. However, both the anti-clonal potential and improvement in overall survival are limited. We investigated the impact of ruxolitinib on formation of superoxide radical and hydrogen peroxide by monocytes in sequentially acquired blood samples from patients with myelofibrosis. We also investigated the impact on RNA and DNA damage by measuring urinary excretion of 8-oxo-Guo and 8-oxo-d-Guo. The formation of superoxide by monocytes was reduced significantly during ruxolitinib therapy, but no impact on the formation of hydrogen peroxide by monocytes or the systemic amount of oxidatively damaged RNA or DNA could be demonstrated. We conclude that ruxolitinib holds little anti-oxidative potential.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Sider (fra-til)1-9
Antal sider9
ISSN1042-8194
DOI
StatusE-pub ahead of print - 20 feb. 2019

ID: 56643066